Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Dec 05, 2024
Update - Notification of buy-back - NEU
Dec 04, 2024
Update - Notification of buy-back - NEU
Nov 15, 2024
Investor presentation, 15 November 2024
Nov 14, 2024
Notification of buy-back - NEU
Nov 14, 2024
Neuren announces A$50m on-market share buy-back program
Nov 07, 2024
Q3 2024 update
Nov 07, 2024
Pause in Trading
Nov 06, 2024
PRV sold for US$150m - Neuren to receive one third
Nov 01, 2024
Updated Share Trading Policy
Oct 28, 2024
Notification of cessation of securities - NEU
Previous
1
2
3
4
5
6
7
Next
